… for increasing hepatic dysfunction; notably, cirrhosis or liver … Two other pharmacokinetics
trials (12 + 22 patients) were … formulations of oral vinflunine alternated with IV administration of …

… Pharmacokinetic studies in elderly patients (≥75 years) did … reduced vinflunine clearance
in patients with renal damage, a … in cases of moderate and severe kidney impairment, …

… most studies in adult cancer patients who received similar doses (17–20). In the current study,
the largest individual group in whom pharmacokinetic … and its newer derivative vinflunine. …

… Mean blood pharmacokinetic parameters of vinflunine in 9 L0070 99 IN 101 Q0 and 9 …
in 77% of the 49 evaluable patients [32]. Data from a Phase I study of the vinflunine–gemcitabine …

… patients with renal or liver impairment. Given the activity demonstrated in phase 1 trials,
vinflunine was evaluated in phase … Results of a phase I/II and pharmacokinetic study of vinflunine …

… Furthermore, the incidence of renal or liver impairment, or both, in patients with cancer will
… studies or from dedicated pharmacokinetic studies done in patients with renal or hepatic …

… phase I trial of tasidotin given iv to patients with advanced solid tumors refractory to standard
treatment … activity in the preclinical studies, tasidotin was administered iv over 30 minutes on …

… ); and the vinca alkaloid vinflunine as single agent or … Vinflunine: a new active drug for
second-line treatment of advanced breast cancer: results of a phase II and pharmacokinetic study …

… this study was manageable with most common grade 3/4 toxicities being neutropenia in 50%
of patients… In this phase III trial VFL did not induce a decrease in health-related quality of life …

… A phase II trial on the basis of an expected maximal tolerated dose combining pazopanib
with vinflunine was planned to continue the phase I study. … This phase I study showed that …